Filing Details
- Accession Number:
- 0001104659-25-026740
- Form Type:
- 13D Filing
- Publication Date:
- 2025-03-20 20:00:00
- Filed By:
- Weidong Yin
- Company:
- Sinovac Biotech Ltd (NASDAQ:SVA)
- Filing Date:
- 2025-03-21
- SEC Url:
- 13D Filing
Ownership Summary
Please notice the below summary table is generated without human intervention and may contain errors. Please refer to the complete filing displayed below for exact figures.
| Name | Sole Voting Power | Shared Voting Power | Sole Dispositive Power | Shared Dispositive Power | Aggregate Amount Owned Power | Percent of Class |
|---|---|---|---|---|---|---|
| Weidong Yin | 6,359,500 | 0 | 6,359,500 | 0 | 6,359,500 | 8.85% |
Filing
|
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549 |
SCHEDULE 13D
Under the Securities Exchange Act of 1934
(Amendment No. 3)
|
SINOVAC BIOTECH LTD. (Name of Issuer) |
Common Shares (Title of Class of Securities) |
P8696W104 (CUSIP Number) |
Weidong Yin No. 39 Shangdi Xi Road, Haidian District Beijing, F4, 100085 86-10-8289-0088 (Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications) |
03/18/2025 (Date of Event Which Requires Filing of This Statement) |
If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§ 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box.
The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the
Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other
provisions of the Act (however, see the Notes).
SCHEDULE 13D
|
| CUSIP No. | P8696W104 |
| 1 |
Name of reporting person
Weidong Yin | ||||||||
| 2 | Check the appropriate box if a member of a Group (See Instructions)
(a)
 (b)
| ||||||||
| 3 | SEC use only | ||||||||
| 4 |
Source of funds (See Instructions)
PF | ||||||||
| 5 |
Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)
| ||||||||
| 6 | Citizenship or place of organization
CHINA
| ||||||||
| Number of Shares Beneficially Owned by Each Reporting Person With: |
| ||||||||
| 11 | Aggregate amount beneficially owned by each reporting person
6,359,500.00 | ||||||||
| 12 | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)
| ||||||||
| 13 | Percent of class represented by amount in Row (11)
8.85 % | ||||||||
| 14 | Type of Reporting Person (See Instructions)
IN |
Comment for Type of Reporting Person:
Comments to item 13: Calculation is based on 71,860,702 Common Shares of the Issuer outstanding as of March 31, 2024 according to the Issuer's annual report on Form 20-F for the fiscal year ended December 31, 2023 (the "2023 Annual Report").
SCHEDULE 13D
|
| Item 1. | Security and Issuer | |
| (a) | Title of Class of Securities:
Common Shares | |
| (b) | Name of Issuer:
SINOVAC BIOTECH LTD. | |
| (c) | Address of Issuer's Principal Executive Offices:
No. 39 Shangdi Xi Rd, Haidian District, Beijing,
CHINA
, 100085. | |
Item 1 Comment:
This Amendment No.3 to Schedule 13D is being filed on behalf of Weidong Yin (the "Reporting Person"), to amend the Schedule 13D relating to the common shares, par value $0.001 per share (the "Common Shares"), of Sinovac Biotech Ltd. (the "Issuer"), filed by the Reporting Person on February 7, 2008, as amended by Amendment No.1 to Schedule 13D filed on February 8, 2016, and Amendment No.2 to Schedule 13D filed on June 27, 2017 (collectively, the "Original Schedule 13D"). The information in each Item below amends the information disclosed under the corresponding Item of the Original Schedule 13D. Except as amended and supplemented herein, the information set forth in the Original Schedule 13D remains unchanged. Capitalized terms used herein have meanings as assigned thereto in the Original Schedule 13D unless defined herein. The information set forth in response to each separate Item below shall be deemed to be a response to all Items where such information is relevant. | ||
| Item 2. | Identity and Background | |
| (a) | Weidong Yin | |
| (b) | The business address of the Reporting Person is No. 39 Shangdi XI St., Haidian District, Beijing, China 100085. | |
| (c) | The Reporting Person's principal occupation is the President and Chief Executive Officer of the Issuer, and the Chairman and General Manager of Sinovac Biotech Co., Ltd., a corporation organized under the laws of the People's Republic of China. | |
| Item 3. | Source and Amount of Funds or Other Consideration | |
Item 3 is hereby amended and supplemented to add the following:
Since the Amendment No.2 to Schedule 13D filed on June 27, 2017, the Reporting Person has acquired 235,000 additional Common Shares through exercise of vested options and vesting of restricted shares previously granted to the Reporting Person by the Issuer. The source of the funds for the exercise of options was provided by the Reporting Person using his personal funds. | ||
| Item 4. | Purpose of Transaction | |
Item 4 is hereby amended and supplemented to add the following:
On March 18, 2025, SAIF Partners IV L.P. ("SAIF") submitted a requisition to the board of directors (the "Board") of the Issuer (the "Requisition"), requesting to convene a special shareholders' meeting (the "Special Shareholders' Meeting") for the purposes of, among other things, nominating a few persons, including the Reporting Person, to the Board. Prior to the submission of the Requisition, SAIF discussed with the Reporting Person the proposal to nominate the Reporting Person to the Board. The Reporting Person and SAIF have not reached any agreement on cooperation.
Except as set forth in this statement, the Reporting Person has no present plan or intention which would result in or relate to any of the transactions described in clauses (a) through (j) of Item 4 of Schedule 13D. The Reporting Person anticipates that further communications may occur with SAIF and other shareholders regarding the Requisition. Depending upon, among other things, the outcome of these communications, the financial condition, results of operations and prospects of the Issuer, conditions in the securities markets, general economic conditions and other factors that the Reporting Person deem relevant, the Reporting Person may take steps and pursue other plans or proposals that relate to or would result in any of the matters set forth in clauses (a) through (j) of Item 4 of Schedule 13D. | ||
| Item 5. | Interest in Securities of the Issuer | |
| (a) | Item 5 is hereby amended and restated as follows:
(a) the Reporting Person currently owns 6,359,500 Common Shares, which represents approximately 8.85% of the total issued and outstanding Common Shares of the Issuer, calculated based on 71,860,702 Common Shares of the Issuer outstanding as of March 31, 2024 according to the 2023 Annual Report. | |
| (b) | (b) The Reporting Person has the sole power to vote or to direct the vote and the sole power to dispose or to direct the disposition of 6,359,500 Common Shares directly owned by him. | |
| (c) | (c) The Reporting Person has not affected any transaction in the Common Shares during the past sixty (60) days. | |
| (d) | (d) Except as otherwise described herein, and to the knowledge of the Reporting Person, no other person has the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, the Common Shares owned by the Reporting Person. | |
| (e) | (e) Not applicable. | |
| Item 6. | Contracts, Arrangements, Understandings or Relationships With Respect to Securities of the Issuer | |
Item 6 is hereby amended and supplemented to add the following:
Item 4 of Amendment No. 3 is incorporated herein by reference. | ||
| SIGNATURE | |
After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.
|
|
|